Supplement No. 13 -- Annual Report IDE #G970088 (Nevyas Excimer Laser) November 4, 1998

· ha

2.0 RISK ANALYSIS

The risk analysis remains unchanged from that submitted with the original IDE. There are no emerging complications or adverse events that alter the risk analysis. The adverse event and complication rates remain low (<1.0%).